Clinical trials: End-Stage Heart Failure
End-Stage Renal Disease, Osteoporosis
Can Alendronate Suppress Calcification and Improve Bone Density in Chronic Peritoneal Dialysis Patients?
Alendronate is a safe and effective drug for treating osteoporosis in post-menopausal women. However, its safety and efficacy in increasing bone mineral density in chronic peritoneal dialysis (PD) patients have not been…
- Trial name
- NCT00261625
- Testing
- alendronate
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
HIV Infections
Assessment of Asymptomatic Heart Disease in Children With HIV
The purpose of this study is to perform cardiac evaluation in HIV-1 (predominantly clade C)infected children by history, physical examination, echocardiogram and plasma N-terminal pro-B-type natriuretic peptide (N-BNP)measurement…
- Trial name
- NCT00426374
- Testing
- echocardiography and blood test
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
Type2diabetes, Heart Failure
N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) in Type 2 Diabetes Mellitus
More than 400 million people have type 2 diabetes (T2D) globally, and the burden of diabetes-related cardiovascular complications is increasing.
- Conditions
- Type2diabetes, Heart Failure, Cardiovascular Complication
- Trial name
- PISCES (NCT05745090)
- Where
- Singapore
- Volunteers
- 1,200 people
- Sponsor
- Singapore General Hospital
Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome
Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients
Patients with kidney failure who require hemodialysis often suffer from anemia (low red blood cell count), heart and blood vessel problems, and a condition involving poor nutrition, inflammation, and hardening of the arteries…
- Conditions
- Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome, Anemia in End Stage Renal Disease, Cardiovascular Diseases (CVD)
- Trial name
- ROXA-HD-MIA (NCT06903559)
- Testing
- Roxadustat, Conventional Anemia Management
- Where
- Egypt
- Volunteers
- 46 people
- Sponsor
- Mansoura University
Kidney Failure, Chronic
Left Ventricular Hypertrophy and Spironolactone in End Stage Renal Disease
The hypothesis of this trial is to assess the effect of spironolactone on heart size and mass
- Trial name
- NCT00548912
- Testing
- Spironolactone
- Where
- United States
- Sponsor
- Dawnmarie DeFazio
End Stage Renal Disease, Cardio-Renal Syndrome
Cardio-Renal Registry
Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality…
- Conditions
- End Stage Renal Disease, Cardio-Renal Syndrome, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- BHCRR (NCT06521801)
- Testing
- Observation
- Where
- United Kingdom
- Volunteers
- 60,000 people
- Sponsor
- Queen Mary University of London
Congenital Disorders
Palliative Care of Children With End-Stage Heart Failure
Palliative care in pediatric oncology and neurology is well described in the literature. There is a lack of information on the care of children terminally ill due to heart failure.
- Trial name
- NCT00327782
- Where
- United States
- Sponsor
- Children's Healthcare of Atlanta
Kidney Failure, Chronic
Autonomic Nervous System Dysfunction in Patients With End-stage Kidney Disease
The prevalence of autonomic nervous system (ANS) dysfunction in patients with end-stage kidney disease (ESKD) is considered to be increased.
- Trial name
- NCT05278702
- Where
- Greece
- Volunteers
- 78 people
- Sponsor
- Aristotle University Of Thessaloniki
End Stage Renal Disease, Arteriovenous Fistula
Changes in Cardiac Structure and Function After Establishment of Autologous Arteriovenous Fistula
This study is a retrospective cohort study aimed at evaluating the impact of autologous arteriovenous fistula (AVF) on the heart, especially the left atrial structure, in patients with end-stage renal disease (ESRD) through a…
- Trial name
- NCT06199609
- Testing
- Hemodialysis pathway, AVF
- Where
- China
- Volunteers
- 2,027 people
- Sponsor
- Haiyan Wang
Heart Failure
REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction
This study is researching an experimental drug called REGN5381 (called "study drug"). The study is focused on patients with heart failure with reduced ejection fraction (ie, the heart is not functioning as well as it should).
- Trial name
- NATRIX-BNP (NCT06237309)
- Testing
- REGN5381
- Where
- 44 sites in United States, Belgium and 10 more
- Volunteers
- 89 people
- Sponsor
- Regeneron Pharmaceuticals
Heart Failure
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure
The BioVAT-HF trial will test the hypothesis that cardiomyocyte implantation via engineered heart muscle (EHM), the proposed investigational medicinal product (IMP; designated "Biological Ventricular Assist Tissue" or BioVAT)…
- Trial name
- BioVAT-HF (NCT04396899)
- Testing
- EHM implantation
- Where
- 3 sites in Germany
- Volunteers
- 53 people
- Sponsor
- University Medical Center Goettingen
Heart Failure With Preserved Ejection Fraction, End Stage Renal Disease on Dialysis
EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
The presence of CKD has been linked to the development of HFpEF. Currently, the treatment for HFpEF is limited. SGLT2i are one of the few drug classes that have proven efficacy in HFpEF in randomized controlled trials.
- Trial name
- EMPA-PRED (NCT06249945)
- Testing
- Empagliflozin 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
End-stage Heart Failure
Long-Term Survival After LVAD Implantation in End-Stage Heart Failure
This is a prospective, observational, multi-center cohort study designed to evaluate long-term survival and clinical outcomes in patients with end-stage heart failure undergoing left ventricular assist device (LVAD) implantation.
- Trial name
- NCT07382284
- Testing
- Left Ventricular Assist Device (LVAD) implantation
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
End-stage Heart Failure
Acute Reno-Cardiac Action of Dapagliflozin In Advanced Heart Failure Patients on Heart Transplant Waiting List
In the DAPA-HF trial, the use of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2 (SGLT2), reduced significantly the risk of worsening heart failure or death from cardiovascular causes compared to placebo among…
- Trial name
- ARCADIA-HF (NCT04782245)
- Testing
- Dapagliflozin 10mg
- Where
- France
- Sponsor
- Hospices Civils de Lyon
Atrial Fibrillation, Atrial Flutter
Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis 2 (SAFE-D2)
People receiving dialysis are more likely to develop atrial fibrillation (AF), an irregular heartbeat that increases the risk of stroke.
- Conditions
- Atrial Fibrillation, Atrial Flutter, End Stage Kidney Disease (ESRD), Dialysis Patients
- Trial name
- SAFE-D2 (NCT07779746)
- Testing
- Eliquis, No oral anticoagulation
- Volunteers
- 848 people
- Sponsor
- Unity Health Toronto
End Stage Liver DIsease
Comparison of Hypothermic Versus Normothermic Ex-vivo Preservation.
Study groups: The study is a multicenter (Pisa and Milan), prospective, randomized study comparing D-HOPE (HMP) vs NMP in DCD and ECD-DBD (extended criteria brain-dead donors).
- Trial name
- DCDNet (NCT04744389)
- Testing
- Hypothermic Machine Perfusion, Normothermic Machine Perfusion
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
End Stage Renal Disease (ESRD), Hemodialysis
Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis
Online hemodiafiltration confers a reduced mortality risk. However, it is not clear why HDF improved survival. To gain more insight in this issue, the effect of 4 dialysis techniques (differing in dialysate temperature and the…
- Conditions
- End Stage Renal Disease (ESRD), Hemodialysis, Hemodiafiltration, Intradialytic Hypotension
- Trial name
- HOLLANT (NCT03249532)
- Testing
- standard hemodialysis, cool hemodialysis, low volume hemodiafiltration
- Where
- 3 sites in Netherlands
- Volunteers
- 40 people
- Sponsor
- Amsterdam UMC, location VUmc
Heart Failure
Comprehensive Management for Terminal Heart Failure Program:
Advanced heart failure presents with various symptoms, including pain, dyspnea, functional decline, reduced quality of life, and physiological deterioration, which can ultimately lead to spiritual distress.
- Trial name
- COMFORT-HF (NCT06892652)
- Testing
- Supportive care measures
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Renal Failure, Left Ventricular Hypertrophy
Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan
The primary objective is to determine if the use of losartan, an angiotensin II receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic…
- Trial name
- NCT00602004
- Testing
- losartan
- Where
- Australia
- Volunteers
- 52 people
- Sponsor
- Melbourne Health
Heart Failure
A Health Economic Evaluation of Using N-Terminal Pro Brain Natriuretic Peptide (NT-Pro BNP) in Acute Heart Failure
Cardiac biomarkers have dramatically impacted the way HF patients are evaluated and managed. In fact, the role of biomarkers has developed to better differentiate HF against other diseases and, to timely initiate and influence…
- Trial name
- NCT03669198
- Testing
- NT-Pro BNP
- Where
- Indonesia
- Volunteers
- 56 people
- Sponsor
- Heart Failure Biomarker Group